The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Abstract
Psilocybin and psilocin are controlled substances in many countries. These are the two main hallucinogenic compounds of the “magic mushrooms” and both act as agonists or partial agonists at 5-hydroxytryptamine (5-HT)2A subtype receptors. During the last few years, psilocybin and psilocin have gained therapeutic relevance but considerable physiological variability between individuals that can influence dose-response and toxicological profile has been reported. This review aims to discuss metabolism of psilocybin and psilocin, by presenting all major and minor psychoactive metabolites. Psilocybin is primarily a pro-drug that is dephosphorylated by alkaline phosphatase to active metabolite psilocin. This last is then further metabolized, psilocin-O-glucuronide being the main urinary metabolite with clinical and forensic relevance in diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Basic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,910
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Basic and clinical pharmacology
Traynor, J. R. (1988) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(88)80021-9 · Cited by 1,131
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Inhibition of monoamine oxidase B in the brains of smokers
Fowler, J. S., Volkow, N. D., Wang, G., Pappas, N. R., Logan, J., MacGregor, R. R., Alexoff, D. L., Shea, C. E., Schlyer, D. J., Wolf, A. P., et al. (1996) · Nature · doi:10.1038/379733a0 · Cited by 657
The pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 2×
“However, most studies are old and do not meet contemporary standards for safety assessment and therefore more controlled studies are needed to ascertain the therapeutic role in certain diseases, especially those psychiatry-related (Passie et al., 2002).”
BackgroundResultMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 435
Research works printed but not linked: 11
- Ballesteros S, 2006, New research on street drugs, 167
- Dinis-Oliveira RJ., 2015, Toxicol Mech Methods, 25, 494
- 10.3109/03602532.2015.1137307 · DOI
- Eivindvik K, 1989, Acta Pharm Nord, 1, 295
- Hofmann A., 1968, Drugs affecting the central nervous system, medicinal research series 2, 169
- Hopf A, 1974, Act Nerv Super, 16, 64
- Horita A., 1963, J Neuropsychiatry, 4, 270
- 10.1016/0006-2952(61)90124-1 · DOI
- Mahmood ZA, 2010, Pak J Pharm Sci, 23, 349
- 10.1007/s00414-012-0796-1 · DOI
- Muller K, 2013, Arch Fur Kriminol, 231, 193
Cited by
Sorted by citations
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
DARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 159
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
“These findings may suggest an indirect role of the dopaminergic system in eliciting hallucinations, as interactions between serotonergic and dopaminergic systems have been established [33].”
BackgroundInfluentialCosta, R. S., Oliveira, N., & Dinis‐Oliveira, R. J. (2019) · Drug Metabolism Reviews · doi:10.1080/03602532.2019.1620763 · Cited by 126
Self-citationMilne, N., Thomsen, P. T., Knudsen, N., Rubaszka, P., Kristensen, M., & Borodina, I. (2020) · Metabolic Engineering · doi:10.1016/j.ymben.2019.12.007 · Cited by 125
“PK strain family background (Entian and Kötter, 2007; Nijkamp et al., 2012).”
Background
Metadata
- Authors
- Dinis-Oliveira, R. J.
- Affiliations
- Department of Sciences, IINFACTS – Institute of Research and Advanced Training in Health Sciences and Technologies, University Institute of Health Sciences (IUCS), CESPU, CRL, Gandra, Portugal;
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2017-01-02
- Volume
- 49
- Issue
- 1
- Pages
- 84-91
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2572835720
- Cited by
- 224
- References
- 65
- Citations by year
- 2026: 21 · 2025: 48 · 2024: 41 · 2023: 38 · 2022: 36 · 2021: 10 · 2020: 17 · 2019: 7 · 2018: 6
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação para a Ciência e a Tecnologia
- FCT (IF/01147/2013)
- FEDER (UID/QUI/50006/2013)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- psilocybin, psilocin, drug metabolism, alkaline phosphatase, prodrugs, urinary metabolites, forensic toxicology, clinical toxicology, 5-HT2A receptor agonists, magic mushrooms, hallucinogens
- MeSH terms
- Hallucinogens, Humans, Prodrugs, Psilocybin, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
